Direct oral anticoagulants versus vitamin-K antagonists in patients with left ventricular thrombus: A systematic review and meta-analysis

Merlo, Andrea Carlo; Benenati, Stefano; Masoero, Giovanni; Zingarelli, Antonio; Ameri, Pietro; Porto, Italo

doi:10.1016/j.vph.2022.106996

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given these clinical benefits of DOACs, some guidelines consider DOACs a promising alternative to vitamin-K antagonists in LVT [ 21 , 22 ], and they are being used increasingly as an off-label alternative. However, the treatment evidence using DOACs for LVT management is limited and controversial [ 23 – 26 ]. Only two RCTs have investigated DOACs vs. warfarin in patients with LVT.…”

Section: Discussionmentioning

confidence: 99%

Clinical profile and prognosis of elderly patients with left ventricular thrombus after anticoagulation

Zhang

Zheng

et al. 2023

Thrombosis J

View full text Add to dashboard Cite

Background Contemporary data regarding the clinical characteristics and prognosis of left ventricular thrombus (LVT) in older adults (aged ≥ 65 years old) are lacking. In this study, we characterized elderly patients with LVT (aged ≥ 65 years old) and investigated the long-term prognosis in this highly vulnerable patient population. Methods This single-center, retrospective study was conducted from January 2017 to December 2022. Patients with a reported LVT were assessed primarily by transthoracic echocardiography (TEE) and classified into two groups: elderly LVT groups and younger LVT groups. All patients were treated with anticoagulant treatment. Major adverse cardiovascular event (MACE) was defined as the composite of all-cause mortality, systemic embolism, and rehospitalization for cardiovascular events. Survival analyses were performed with the Kaplan-Meier method and Cox proportional-hazard model. Results A total of 315 eligible patients were included. Compared to the younger LVT group (n = 171), the elderly LVT group (n = 144) had a lower proportion of males and lower serum creatinine clearance, as well as a higher level of NT-proBNP, and a higher rate of history of systemic embolism. LVT resolution occurred in 59.7% and 69.0% of patients in the elderly LVT group and younger LVT group, respectively, with no significant difference (adjusted HR, 0.97; 95% CI, 0.74–1.28; P = 0.836). Yet, elderly patients with LVT, had higher prevalence rates of MACE (adjusted HR, 1.52; 95% CI, 1.10–2.11; P = 0.012), systemic embolism (adjusted HR, 2.81; 95% CI, 1.20–6.59; P = 0.017) and all-cause mortality (adjusted HR, 2.20; 95% CI, 1.29–3.74; P = 0.004) compared with younger patients with LVT. After adjusting for mortality in the Fine–Gray model, similar results were observed. Additionally, patients treated with different anticoagulation therapies (DOACs vs. warfarin) achieved a similar improvement in prognosis (P > 0.05) or LVT resolution (P > 0.05) in elderly patients with LVT. Conclusions Our results found that elderly patients experiencing LVT have a poor prognosis compared with the younger ones. Clinical prognosis in elderly patients did not significantly differ with the type of anticoagulant used. With aging societies worldwide, further evidence of antithrombotic therapy in elderly individuals with LVT is necessary.

show abstract

Section: Discussionmentioning

confidence: 99%